Novo Nordisk A/S (NYSE:NVO) shares traded -2.09% lower at $192.63 on Wall Street last session.
In accordance with the data, 27 analysts cover Novo Nordisk A/S (NYSE:NVO). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $117.50 and a low of $52.70, we find $99.44. Given the previous closing price of $196.75, this indicates a potential downside of -49.46 percent. NVO stock price is now 10.95% away from the 50-day moving average and 24.44% away from the 200-day moving average. The market capitalization of the company currently stands at $329.53B.
It has been rated a hold by 6 analysts and a buy by 16. Brokers who have rated the stock have averaged $96.10 as their price target over the next twelve months.
A total of 26.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NVO stock. A new stake in Novo Nordisk A/S shares was purchased by 1832 ASSET MANAGEMENT L.P. during the first quarter worth $224,498,000. TIGER GLOBAL MANAGEMENT LLC invested $122,224,000 in shares of NVO during the first quarter. In the first quarter, QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in Novo Nordisk A/S valued at approximately $29,479,000. MARTIN INVESTMENT MANAGEMENT, LLC acquired a new stake in NVO for approximately $28,779,000. COATUE MANAGEMENT LLC purchased a new stake in NVO valued at around $26,066,000 in the second quarter. In total, there are 1,301 active investors with 8.40% ownership of the company’s stock.
Novo Nordisk A/S (NYSE: NVO) opened at $192.41 on Wednesday. During the past 12 months, Novo Nordisk A/S has had a low of $95.02 and a high of $201.76. As of last week, the company has a debt-to-equity ratio of 0.28, a current ratio of 0.90, and a quick ratio of 0.70. According to the stock market information, the enterprise value for the company is $432.99B, which is based on a 45.28 price-to-earnings ratio, a 16.17 price-to-earnings-growth ratio, and a beta of 0.43. The fifty day moving average price for NVO is $174.28 and a two-hundred day moving average price translates $155.17 for the stock.
The latest earnings results from Novo Nordisk A/S (NYSE: NVO) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at $2.51, beating analysts’ expectations of $1.27 by 1.24. This compares to $0.84 EPS in the same period last year. The net profit margin was 33.40% and return on equity was 81.40% for NVO. The company reported revenue of $7.93 billion for the quarter, compared to $5.9 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 34.44 percent. For the current quarter, analysts expect NVO to generate $7.84B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 08/29/2023. Investors who held shares on 08/21/2023 were paid a $0.8835613 dividend. On an annualized basis, this represents a $2.06 dividend and a 1.07% percent yield. There was an ex-dividend date of 08/18/2023 for this dividend. In terms of dividend payout ratio, NVO is presently at 33.02%.
Novo Nordisk A/S(NVO) Company Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
